Stivarga to be tested as therapy for glioblastoma

Bayer’s (BAYN: DE) Stivarga (regorafenib) will be subject to a new trial run by The Global Coalition for Adaptive Research (GCAR), called GBM AGILE.

GCAR says the study is “a revolutionary patient-centered adaptive platform trial that will evaluate multiple therapies for patients with newly-diagnosed and recurrent glioblastoma.”

Stivarga is already approved for the treatment of patients with colorectal and gastrointestinal stromal tumors in several countries, including the USA, Europe and Japan.